

1 Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced  
2 immunity from seasonal human coronavirus humoral responses

3  
4 Eric D. Laing<sup>1\*</sup>, Spencer L. Sterling<sup>1,2</sup>, Stephanie A. Richard<sup>2,3</sup>, Nusrat J. Epsi<sup>2,3</sup>, Si'Ana  
5 Coggins<sup>1,2</sup>, Emily C. Samuels<sup>1,2</sup>, Shreshta Phogat<sup>1,2</sup>, Lianying Yan<sup>1,2</sup>, Nicole Moreno<sup>2,3</sup>, Christian  
6 L. Coles<sup>2,3</sup>, Matthew Drew<sup>4</sup>, Jennifer Mehalko<sup>4</sup>, Caroline E. English<sup>2,3</sup>, Scott Merritt<sup>2,3,5</sup>, Katrin  
7 Mende<sup>2,3,5</sup>, Vincent J. Munster<sup>6</sup>, Emmie de Wit<sup>6</sup>, Kevin K. Chung<sup>7</sup>, Eugene V. Millar<sup>2,3</sup>, David R.  
8 Tribble<sup>3</sup>, Mark P. Simons<sup>1,3</sup>, Simon D. Pollett<sup>2,3</sup>, Brian K. Agan<sup>2,3</sup>, Dominic Esposito<sup>4</sup>, Charlotte  
9 Lanteri<sup>2</sup>, G. Travis Clifton<sup>5</sup>, Edward Mitre<sup>1</sup>, Timothy H. Burgess<sup>2</sup>, and Christopher C. Broder<sup>1\*</sup>

10  
11

12 <sup>1</sup>Department of Microbiology and Immunology, Uniformed Services University of the Health  
13 Sciences, Bethesda, MD, USA

14 <sup>2</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD  
15 USA

16 <sup>3</sup>Infectious Disease Clinical Research Program, Department of Preventive Medicine and  
17 Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

18 <sup>4</sup>Protein Expression Laboratory, National Cancer Institute RAS Initiative, Frederick National  
19 Laboratory for Cancer Research, Frederick, MD, USA

20 <sup>5</sup>Brooke Army Medical Center, JBSA Fort Sam Houston, TX, USA

21 <sup>6</sup>Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and  
22 Infectious Diseases, National Institutes of Health, Hamilton, MT, USA

23 <sup>7</sup>Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD,  
24 USA

25  
26

27

28 \*Correspondence

29 Eric D. Laing, PhD

30 Department of Microbiology and Immunology

31 Uniformed Services University, Bethesda, MD 20814

32 Phone: 301-295-9884

33 Fax: 301-295-1545

34 Email: eric.laing@usuhs.edu

35 Christopher C. Broder, PhD

36 Department of Microbiology and Immunology

37 Uniformed Services University, Bethesda, MD 20814

38 Phone: 301-295-3401

39 Fax: 301-295-1545

40 Email: christopher.broder@usuhs.edu

41

42 **ABSTRACT**

43 Sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospital-  
44 based SARS-CoV-2 sero-surveillance. With the rollout of SARS-CoV-2 vaccines, such assays  
45 must be able to distinguish vaccine from natural immunity to SARS-CoV-2 and related human  
46 coronaviruses. Here, we developed and implemented multiplex microsphere-based  
47 immunoassay strategies for COVID-19 antibody studies that incorporates spike protein trimers of  
48 SARS-CoV-2 and the endemic seasonal human coronaviruses (HCoV), enabling high  
49 throughout measurement of pre-existing cross-reactive antibodies. We varied SARS-CoV-2  
50 antigen compositions within the multiplex assay, allowing direct comparisons of the effects of  
51 spike protein, receptor-binding domain protein (RBD) and nucleocapsid protein (NP) based  
52 SARS-CoV-2 antibody detection. Multiplex immunoassay performance characteristics are  
53 antigen-dependent, and sensitivities and specificities range 92-99% and 94-100%, respectively,  
54 for human subject samples collected as early as 7-10 days from symptom onset. SARS-CoV-2  
55 spike and RBD had a strong correlative relationship for the detection of IgG. Correlation  
56 between detectable IgG reactive with spike and NP also had strong relationship, however,  
57 several PCR-positive and spike IgG-positive serum samples were NP IgG-negative. This spike  
58 and NP multiplex immunoassay has the potential to be useful for differentiation between  
59 vaccination and natural infection induced antibody responses. We also assessed the induction  
60 of *de novo* SARS-CoV-2 IgG cross reactions with SARS-CoV and MERS-CoV spike proteins.  
61 Furthermore, multiplex immunoassays that incorporate spike proteins of SARS-CoV-2 and  
62 HCoVs will permit investigations into the influence of HCoV antibodies on COVID-19 clinical  
63 outcomes and SARS-CoV-2 antibody durability.

64

65

66

## 67 INTRODUCTION

68 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel zoonotic  
69 positive-sense, single-stranded, RNA virus responsible for the third viral pandemic of the 21<sup>st</sup>  
70 century, and the third zoonotic coronavirus outbreak in the past 20 years (1, 2). At this time,  
71 SARS-CoV-2 has globally caused 106 million COVID-19 cases and over 2 million COVID-19  
72 related deaths. Serology studies have demonstrated SARS-CoV-2 infection elicits an antibody  
73 responses that can persist for as long as 8 months (3), and that the magnitude of the antibody  
74 response is associated with COVID-19 severity (4, 5). A variety of antibody tests have been  
75 developed and granted Emergency Use Authorization (EUA) by the U.S. Food and Drug  
76 Administration (6), with the majority of these tests designed to assess for antibodies against the  
77 SARS-CoV-2 spike (S) envelope glycoprotein, the primary target of virus-neutralizing antibodies  
78 (7), in either its native-like oligomer conformation, or against one of its protein subunits or  
79 domains.

80 A native-like SARS-CoV-2 prefusion stabilized S-2P glycoprotein ectodomain trimer  
81 (hereafter referred to as spike) (8, 9) has been adopted for large-scale SARS-CoV-2 antigen-  
82 based serology and serosurveillance (10-13). The receptor-binding domain (RBD) located within  
83 the more variable S1 subunit of the S glycoprotein, lacking potentially conserved epitopes with  
84 endemic seasonal human coronavirus (HCoV) S glycoproteins and conferring specificity for  
85 SARS-CoV-2, has also been extensively used in antigen-based immunoassays (10, 14-16).  
86 Furthermore, immunoassay detection of IgG antibodies that can bind to RBD has been used as  
87 a surrogate for neutralization tests which require cell-culture, pseudoviruses, or high biosafety-  
88 containment and wild-type SARS-CoV-2 (15, 17, 18). Lastly, the SARS-CoV-2 nucleocapsid  
89 protein (NP) has been used in several lateral flow and antigen-based COVID-19 serology tests  
90 (6).

91 A handful of microsphere-based SARS-CoV-2 serology assays have been developed,  
92 facilitating high throughput multiplex strategies for antibody detection (19-23). Multiplex

93 microsphere-based immunoassays (MMIA) have several advantages over traditional  
94 immunoassays including optical improvements in sensitivity and specificity, as well as  
95 reductions in sample volume and materials to test for antigen-specific antibodies since multiple  
96 target antibodies can be simultaneously captured with multiple antigens coupled to unique  
97 fluorescent microspheres. Additionally, multiplexing systems, e.g. Luminex xMAP-based  
98 platforms, have a large dynamic range, which have been shown to be more sensitive than  
99 ELISA for the detection of antibodies to viral infections (21, 24-26). As COVID-19 vaccine  
100 rollouts continue in the U.S., MMIA strategies allowing simultaneous detection of spike and NP  
101 reactive antibodies may facilitate differentiation of SARS-CoV-2 natural infection and  
102 vaccination (27), as all current U.S. FDA EUA COVID-19 vaccines induce humoral responses to  
103 the S glycoprotein (28, 29).

104 We have previously utilized a SARS-CoV-2 MMIA in cross-sectional serological analysis  
105 of military healthcare workers deployed to the Jacob K. Javits Center COVID-19 field hospital,  
106 (Javits Medical Station) (30) and U.S. Navy personnel deployed on the USNS COMFORT (31)  
107 and during the first SARS-CoV-2 epidemic wave in New York City, NY. Utilizing sera from three  
108 cohorts, a) SARS-CoV-2 naïve serum samples from the Acute Respiratory Infection Consortium  
109 Natural History Study (ARIC) collected from 2012 – 2018 (32), b) serum samples from PCR-  
110 confirmed SARS-CoV-2 subjects enrolled in the ongoing Epidemiology, Immunology, and  
111 Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) study  
112 and c) serum samples from hospitalized patients at the Javits Medical Station (JMS) who  
113 participated in the COVID-19 Antibody Prevalence in Military Personnel Deployed to New York  
114 (CAMP-NYC) study (30), we describe the utility of three distinct antigen-based MMIA for  
115 COVID-19 serology studies.

116 Initially, we examined sensitivity differences in detection of SARS-CoV-2 antibodies  
117 between widely used antigens: SARS-CoV-2 prefusion stabilized S-2P glycoprotein ectodomain  
118 trimer (spike), a monomeric receptor-binding domain (RBD) protein and nucleoprotein (NP).

119 Additionally, given the high seroprevalence of the seasonal HCoVs (33-35) and evidence of pre-  
120 existing antibody cross-reactivity with SARS-CoV S glycoprotein (36, 37), we validated  
121 improvements to assay specificity by the concurrent measurement of SARS-CoV-2 and HCoV-  
122 specific immunoglobulin G (IgG) in a multiplex approach and report the stimulation of cross-  
123 reactive antibody responses across ARIC, EPICC and JMS cohorts. Furthermore, we  
124 standardized SARS-CoV-2 and HCoV MMIA SARS-CoV-2 IgG detection in paired venous and  
125 capillary blood specimens collected by serum separator tubes (SST) and dried blood spots  
126 (DBS), respectively.

127 The objectives of this study were to develop and validate a high throughput antigen  
128 based assay which can discriminate SARS-CoV-2 from seasonal human coronavirus (HCoV)  
129 infections, as well as SARS-CoV-2 vaccination, including from specimens collected through self-  
130 collected DBS specimens which may greatly facilitate the performance of post vaccination  
131 serosurveys and vaccine effectiveness studies. This SARS-CoV-2/HCoV MMIA strategy also  
132 has the potential to enhance investigations of the interplay of pre-existing seasonal HCoV  
133 antibodies on SARS-CoV-2-specific antibody durability, COVID-19 symptom presentation and  
134 disease severity, and we present exploratory results here which show that coronavirus  
135 serological cross-reactivity is influenced by the severity of SARS-CoV-2 illness.

136

## 137 **MATERIALS AND METHODS**

### 138 *Recombinant protein antigens and microsphere coupling*

139 Prefusion stabilized SARS-CoV-2 spike (S) glycoprotein was used in serology testing to  
140 capture the full humoral response including all conformation-dependent antibodies. Prefusion  
141 stabilized SARS-CoV-2 S-2P glycoprotein ectodomain trimers (spike protein) and SARS-CoV-2  
142 RBD were purchased from LakePharma, Inc. (Hopkinton, MA USA). This SARS-CoV-2 spike  
143 protein shares an equivalent ectodomain with the NIH Vaccine Research Center designed  
144 SARS-CoV-2 spike protein, and the Mount Sinai SARS-CoV-2 spike protein used in ELISA-

145 based serology (9, 10, 16, 38, 39).

146 Design and expression of prefusion stabilized betacoronavirus ( $\beta$ -CoV) HCoV-HKU1,  
147 HCoV-OC43, SARS-CoV and MERS-CoV spike proteins have been previously described (37,  
148 38). The alphacoronavirus ( $\alpha$ -CoV) HCoV-229E and HCoV-NL63 spike proteins were similarly  
149 constructed and prepared (LakePharma, Inc.). The SARS-CoV-2 nucleocapsid protein (NP) was  
150 purchased from RayBiotech, Inc. (Peachtree Corners, GA, USA). A mock antigen, consisting of  
151 cell culture supernatant from non-transfected HEK cells was collected via centrifugation then  
152 filtered through a 0.22  $\mu$ M PES filter to remove debris. Mock antigen-coupled beads were  
153 included in each microtiter well to control for non-specific/artificial antisera binding; samples that  
154 react with the mock antigen above an established 3-fold cutoff were retested. Proteins were  
155 coupled to carboxylated magnetic MagPlex microspheres (Bio-Rad, Hercules, CA) at a protein  
156 to microsphere ratio of 15  $\mu$ g:100  $\mu$ L, and antigen-coupled microspheres were resuspended in a  
157 final volume of 650  $\mu$ L following manufacturer's protocol (Bio-Rad) for amine coupling.

#### 158 *Participant enrollment and sera collection*

159 SARS-CoV-2 negative human serum specimens utilized were from sera collected from  
160 2012 – 2018 in the ARIC Natural History Study (IDCRP-045) (32). ARIC sera predate the  
161 COVID-19 pandemic and were collected from subjects who had nasopharyngeal swabs tested  
162 by nucleic acid amplification methods for virus etiologies of acute respiratory infections; samples  
163 collected from individuals with rhinovirus and the seasonal HCoVs, HCoV-OC43, -HKU1, -229E  
164 and -NL63 were used (40). In addition, we utilized serum samples collected since the  
165 emergence of SARS-CoV-2 under the IDCRP EPICC (IDCRP-085) protocol; a prospective,  
166 longitudinal observational cohort study to analyze the natural history of COVID-19 disease.  
167 Subjects were enrolled at five hospitals across the continental U.S., including Walter Reed  
168 National Military Medical Center (WRNMMC, Bethesda, MD), Brooke Army Medical Center  
169 (BAMC, San Antonio, TX), Naval Medical Center San Diego (NMCSD, San Diego, CA),

170 Madigan Army Medical Center (MAMC, Tacoma, WA) and Fort Belvoir Community Hospital  
171 (FBCH, Fort Belvoir, VA). Subjects of all race and gender seeking treatment for acute illness at  
172 these military hospitals were offered enrollment into the ARIC, IDCRP-045 and EPICC, IDCRP-  
173 085 protocols. EPICC study enrollment included subjects with laboratory-confirmed SARS-CoV-  
174 2 infection by nucleic acid amplification test, subjects with compatible illness in whom SARS-  
175 CoV-2 infection is initially suspected but PCR confirmed as SARS-CoV-2 negative, and  
176 asymptomatic subjects at risk of SARS-CoV-2 due to high risk exposure. Additionally, serum  
177 samples from 35 subjects undergoing treatment at JMS under the CAMP-NYC protocol were  
178 included in the assessment of assay performance. ARIC (IDCRP-045), EPICC (IDCRP-085)  
179 and CAMP-NYC protocols were approved by the Uniformed Services University Institutional  
180 Review Board.

#### 181 *Multiplex microsphere-based immunoassay screening procedures*

182 Three antigen-distinct MMIA were established: a)  $\beta$ -CoV MMIA that included SARS-  
183 CoV-2 spike and RBD, and SARS-CoV, MERS-CoV, HCoV-HKU1 and HCoV-OC43 spike; b) a  
184 SARS-CoV-2 and HCoV MMIA (SARS-2/HCoV) that included SARS-CoV-2, HCoV-HKU1,  
185 HCoV-OC43, HCoV-229E and HCoV-NL63 spike; and c) a SARS-CoV-2 spike and NP MMIA  
186 (SARS-2 spike/NP) (Table 1).

187 Serum samples were collected from venipuncture in serum separator tubes, processed  
188 and stored at -80 °C in 250  $\mu$ L aliquots until use. At-home blood collection was performed with  
189 Mitra Collection Kits (Neoteryx, Torrance, CA, USA). Microsampler tip dried blood spots (DBS)  
190 were placed into deep-96-well microtiter plates containing 400  $\mu$ L of 1X PBS-T and eluted  
191 overnight at 4 °C with agitation, 300 rpm. The duplicate microsampler tip DBS eluents were  
192 combined to 800  $\mu$ L, vortexed, aliquoted to 200  $\mu$ L and stored at -80 °C until antibody testing.  
193 For each 96-well plate, a multiplex master mix of antigen-coupled microspheres was made by  
194 diluting 100  $\mu$ L of each antigen-coupled microsphere working stock into 10 mL (1:100) 1XPBS

195 without calcium and magnesium (Corning Inc., Corning, NY) (all mentions of PBS refer to  
196 solutions without calcium and magnesium), and 100  $\mu$ L of this master mix were added to each  
197 well so that each well contained 1  $\mu$ L (~23 ng) of each antigen-coupled microsphere per well.  
198 Wells were washed with 1XPBS + 0.05% Tween20 + 0.02% sodium azide two times. One  
199 hundred microliters of each serum sample was added to each well. Serum samples were diluted  
200 within a class II type A2 biological safety cabinet (BSC) then subjected to thermal inactivation  
201 for 30 min at 60 °C. Human serum samples (1.25  $\mu$ L) were diluted 1:400 in PBS and eluted  
202 DBS aliquots were diluted 1:10 in PBS, and tested in technical duplicate A and B plates.  
203 Controls on each duplicate plate included a PBS blank (wells: A1, B1, G12, H12) and SARS-  
204 CoV-2 PCR-confirmed positive (C1, F12) and negative (D1, E12) serum sample. SARS-CoV-2  
205 qualified controls for established expected inter- and intra-plate variations.

206         Samples were incubated at room temperature for 45 minutes with agitation (900 rpm),  
207 and plates were washed three times by an automated plate washer. Secondary antibody (goat  
208 anti-human IgG cross-absorbed biotin-conjugated or goat anti-human IgM cross-absorbed  
209 biotin-conjugated; Thermo Fisher Scientific, Waltham, MA) was diluted 1:5000 in 1XPBS +  
210 0.05% Tween20 (PBST) and 100  $\mu$ L of each secondary was added to each well and incubated  
211 for 45 minutes with agitation, and plates were washed three times. Streptavidin-phycoerythrin  
212 (Bio-Rad) was diluted 1:1000 in PBST and 100  $\mu$ L was then added to each well and incubated  
213 for 30 minutes with agitation, and plates were washed three times. Lastly, 100  $\mu$ L of PBST was  
214 added to each well and plates were resuspended by agitation for 5 minutes. Plates were read  
215 on Bio-Plex 200 multiplexing systems (Bio-Rad) with PMT voltage setting to the High RP1 target  
216 and 100 bead count requirements. Antibody levels are reported as quantified median  
217 fluorescence intensity (MFI). The average MFI of the four PBS-blank wells on each plate were  
218 subtracted from the MFI of each sample well and MFI values for samples are reported as the  
219 PBS adjusted average from duplicate plates.



## 220 *Threshold cutoffs for SARS-CoV-2 antibody*

221 To establish threshold cutoffs for SARS-CoV-2 spike protein-specific antibody reactivity,  
222 we tested 127 archival acute and convalescent human serum samples from ARIC. Acute and  
223 convalescent serum samples were collected within approximately three and twenty-eight days  
224 of symptom onset, respectively. We established a cut-off of three standard deviations above the  
225 mean (99.7% probability) MFI of archival HCoV PCR-confirmed convalescent serum samples  
226 (n= 43) to establish a positivity threshold for detection of SARS-CoV-2 spike protein reactive  
227 IgG and IgM antibodies. The remaining 84 archival serum samples were tested against this MFI  
228 threshold cutoff for SARS-CoV-2 reactivity. The 127 archival ARIC serum samples were tested  
229 in technical duplicates in three independent experiments ( $\beta$ -CoV MMIA) and two independent  
230 experiments (SARS-2/HCoV MMIA and SARS-2 spike/NP MMIA) to establish threshold cutoffs  
231 and specificity for SARS-CoV-2. A highly reactive HKU1 PCR+ convalescent serum sample to  
232 SARS-CoV-2 NP was excluded in the 99.7% threshold sacrificing specificity for sensitivity.

## 233 *Non-human primate sera*

234 Archived sera were used from rhesus macaques inoculated with a total dose of  $2.6 \times 10^6$   
235 TCID<sub>50</sub> of SARS-CoV-2 via a combination of intranasal, intratracheal, oral and ocular  
236 inoculation routes (41). Serum samples were collected at dpi 0 (baseline) and 21. SARS-CoV-2  
237 IgG antibody seroconversion was determined as a 4-fold increase in MFI compared to the  
238 baseline sera collection.

## 239 *Statistical analysis*

240 Figures were generated and statistical analyses were performed in GraphPad Prism  
241 version 7.0. When comparing zoonotic and endemic spike-specific IgG levels, MFI values were  
242 log<sub>10</sub>-transformed, checked for normality and parametric unpaired t-tests were employed to  
243 compare EPICC and JMS cohort to ARIC; statistical analysis with one-way ANOVA and Holm-  
244 Sidak's multiple comparison were also utilized. When normality was not met, non-parametric

245 unpaired Mann Whitney tests were performed. The positive predictive value and negative  
246 predictive value were calculated with MedCalc statistical software. ROC analysis was conducted  
247 using R version 4.0.2.

248

## 249 **RESULTS**

### 250 *Generation of threshold cutoffs for SARS-CoV-2 antibodies*


251 Despite low sequence similarity and identity between SARS-CoV-2 spike protein and  
252 seasonal HCoV spike proteins, pre-existing antibodies induced by prior infections with seasonal  
253 HCoVs are potentially cross-reactive, seemingly driven by conserved epitopes shared by the  
254 SARS-CoV-2 S glycoprotein S2 subunit (36, 37, 42). To enhance specificity for SARS-CoV-2  
255 antibody detection, we established antibody positive/negative thresholds with SARS-CoV-2  
256 naïve serum samples from human subjects with PCR-confirmed HCoV infections via the ARIC  
257 study (32, 40). First, we examined pre-existing IgG and IgM reactivity to SARS-CoV-2 antigens:  
258 spike, RBD and NP. IgG in convalescent sera collected ~28 days after PCR-confirmed HCoV  
259 infections were more reactive with SARS-CoV-2 spike and NP than paired acute sera (Fig. 1A-  
260 C), suggesting that in a subset of persons recent HCoV-infection induces antibodies that are  
261 reactive with SARS-CoV-2 S glycoprotein and NP antigens. In some specific samples IgG in  
262 acute serum were more reactive with RBD (Fig. 1B).

263

264

265

266



279 **Figure 1. Pre-existing cross-reactivity with SARS-CoV-2 antigens informs threshold**  
280 **cutoffs for antibody positivity.** Acute and convalescent serum samples from SARS-CoV-2  
281 naïve HCoV PCR-positive subjects were tested in  $\beta$ -CoV **(A-B)** and SARS-CoV-2 spike/NP **(C)**  
282 MMIA. SARS-CoV-2 antigens are indicated. Subjects are grouped together based on HCoV  
283 PCR confirmation, HCoV-OC43 (n= 16), HCoV-HKU1 (n= 6), HCoV-NL63 (n= 13) and HCoV-  
284 229E (n= 10). MFI, median fluorescence intensity; IgG MFI values represent the MEAN of  
285 independent experiments performed in technical duplicates.

286

287

288

289

290

291

292           Second, accounting for this pre-existing cross-reactivity, we applied conventional  
293 probability distributions three standard deviations above the mean (99.7%) of these ARIC  
294 SARS-CoV-2 naïve HCoV-PCR confirmed convalescent sera to generate threshold cutoffs for  
295 SARS-CoV-2 positive antibodies (Fig. S1A-C). In addition to 99.7% probability distribution of  
296 ARIC sera, receiver operating characteristic (ROC) curve analysis of sera collected from SARS-  
297 CoV-2 RT-PCR confirmed subjects enrolled in the ongoing EPICC protocol were applied for  
298 spike, RBD and NP reactive IgG thresholds (Fig. S2A-D). ROC analyses identified MFI cutoff  
299 values, 4853 and 4144, retaining 100% sensitivity and 100% sensitivity with spike in both  $\beta$ -CoV  
300 and SARS-2/HCoV MMIA, respectively. When we applied this ROC curve value as a threshold  
301 for SARS-CoV-2 spike reactive IgG, we identified 2/43 (4.7%) serum samples from SARS-CoV-  
302 2 naïve ARIC with confirmed recent HCoV-OC43 and HCoV-229E infections above this cutoff  
303 (Fig. 1A). Further ROC analyses of antigen-specific IgG reactivity identified optimal MFI cutoff  
304 values for RBD of 4622 MFI (sensitivity= 82.7%, specificity= 91.5%) and NP of 6372 MFI  
305 (sensitivity= 90.5%, specificity= 100%). Pre-existing antibody reactivity with SARS-CoV-2 RBD  
306 and SARS-CoV-NP was further observed in 4/43 (9.3%) and 2/43 (4.7%), respectively, of ARIC  
307 serum samples from subjects with recent HCoV infections (Fig. 1B-C). These two distinct  
308 approaches to establish SARS-CoV-2 positive antibody threshold cutoffs resulted in very narrow  
309 positive/negative indeterminate ranges between the ARIC generated 99.7% threshold cutoff and  
310 the EPICC generated ROC curve threshold cutoff for spike, RBD and NP reactive IgG (Table 2).

311

### 312 *Validation of multiplex microsphere-based immunoassay strategies*

313           Next, we examined the influence of multiple antigen targets and multiplex composition  
314 on the diagnostic specificity and sensitivity of the MMIA strategies. Measurements of MMIA  
315 specificities were made using ARIC human serum samples, representing HCoV PCR-positive  
316 acute sera, rhinovirus PCR-positive acute/convalescent sera, and acute/convalescent sera from  
317 'no pathogen detected' subjects, and were tested against our established threshold cutoffs. For

318 sensitivity measurements, we utilized sera from SARS-CoV-2 PCR-confirmed human  
319 participants in EPICC and CAMP-NYC. Serum samples collected 10 – 73 dpso, median 23.5  
320 dpso (IQR= 9.25) from hospitalized patients (n=35) at the JMS who participated in the cross-  
321 sectional CAMP-NYC protocol were screened for SARS-CoV-2 IgG antibody reactivity with  
322 MMIA strategies.

323 In the  $\beta$ -CoV and SARS-2 S-2P/NP MMIA strategies, serum samples (n= 116) collected  
324 10 – 60 days post-symptom onset (dpso), median 37 dpso (IQR= 13.75), from SARS-CoV-2  
325 PCR-positive outpatient (n= 62) and hospitalized patient (n= 54) participants enrolled in the  
326 EPICC protocol were tested for IgG reactivity with SARS-CoV-2 spike and RBD. Using the  
327 established threshold cutoffs, SARS-CoV-2 S-2P reactive IgG antibodies were only detected in  
328 PCR positive subjects from EPICC and JMS, retaining 100% specificity (Fig. 2A). The  
329 respective geometric mean IgG level with 95% confidence intervals (CI) against spike and RBD  
330 were 20,542 MFI (18,806-22,440 CI) and 18,271 MFI (16,251-20,542 CI) for EPICC samples  
331 (Fig. 2A-B), whereas, the geometric mean IgG level against spike and RBD were 26,829 MFI  
332 (25,757-27,945 CI) and 25,869 MFI (24,670-27,126) for JMS samples (Fig. 2A-B). These  
333 differences in geometric mean IgG levels are likely a reflection of COVID-19 severity as all JMS  
334 participants were hospitalized while outpatients made up a majority of the EPICC participants.  
335 Simultaneously utilizing spike and RBD proteins to capture target SARS-CoV-2 reactive IgG, we  
336 observed a significant correlation and strong linear relationship (Spearman r value= 0.9748;  $P$ =  
337 < 0.0001) between antibody binding to spike and RBD (Fig. 2C). SARS-CoV-2 spike reactive  
338 IgG antibody detection by  $\beta$ -CoV MMIA was calculated with 95% CI as follows, sensitivity=  
339 99.3% (96.3%-99.9% CI), specificity= 100% (95.7%-100.0% CI). Assuming a US disease  
340 prevalence of 5.0%, the the  $\beta$ -CoV MMIA had a positive predictive value (PPV) = 100.0%, and  
341 negative predictive value (NPV) = 99.9% (99.8%-100.00% CI) (Table 3). Comparatively, utility of  
342 SARS-CoV-2 RBD for IgG detection had a slightly reduced sensitivity= 96.0% (91.5%-98.5%

343 CI), specificity= 96.4% (89.9%-99.2% CI), PPV= 58.6% (31.8%-81.1% CI) and NPV= 99.8%  
344 (99.5%-99.9% CI) with a 5.0% prevalence estimate.

345 Utility of a SARS-CoV-2 NP antigen was explored in a SARS-CoV-2 spike/NP MMIA  
346 able to simultaneously capture antibodies specific to both S glycoprotein and NP. The  
347 respective, geometric mean IgG levels of spike and NP were 25,526 MFI (23,703-27,490 CI)  
348 and 20,165 MFI (17,241-23,584 CI) in EPICC, and 30,723 MFI (29,434-32,069) and 30,268 MFI  
349 (29,350-31,215 CI) in JMS sera. In the absence of HCoV spike, two ARIC serum samples were  
350 cross-reactive with SARS-CoV-2 spike above the positive threshold, and all SARS-CoV-2 PCR-  
351 confirmed samples had detectable spike reactive IgG (Fig. 2D). Five ARIC samples were cross-  
352 reactive with SARS-CoV-2 NP and 11 EPICC subjects developed IgG to spike but not NP (Fig.  
353 2E). Regardless, the correlation between spike and NP was statistically significant (Spearman r  
354 value= 0.898;  $P = < 0.0001$ ) (Fig. 2F). Antigen-specific immune responses to spike and NP have  
355 been observed in COVID-19 patients and are associated with disease severity and older age (4,  
356 43, 44). The performance of SARS-CoV-2 NP IgG assay sensitivity= 92.7% (87.3%-96.3% CI),  
357 specificity= 94.1% (86.7%-98.0% CI), PPV= 45.0% (25.9%-65.8% CI) and NPV= 99.6% (99.3%-  
358 99.8%) (Table 4).

359

360

361

362

363


364

365

366

367

368



369

370 **Figure 2. Detection of SARS-CoV-2 reactive serum IgG with S glycoprotein and**  
371 **nucleoprotein antigens.** Serum samples were tested in  $\beta$ -CoV MMIA for reactivity with SARS-  
372 CoV-2 spike **(A)** and RBD **(B)**. **(C)** Correlation analysis of IgG binding to SARS-CoV-2 spike and  
373 RBD when tested simultaneously in the  $\beta$ -CoV MMIA. Serum samples were tested in SARS-2  
374 spike/NP MMIA for reactivity with SARS-CoV-2 spike **(D)** and NP **(E)**. **(F)** Correlation analysis of  
375 IgG binding to SARS-CoV-2 spike and NP when tested simultaneously in the SARS-2 spike/NP  
376 MMIA.

377

378

379

380

381

382

383

384 SARS-CoV-2 IgG seroconversion has been detected early after exposure and  
385 sometimes in parallel with IgM seroconversion (45-47). For SARS-CoV-2 IgM detection, again  
386 we applied a ROC analysis threshold, 1445 MFI (Fig. S3A), which was more conservative than  
387 the 99.7% probability threshold cutoff, 840 MFI (Fig. S3B). No ARIC sera were reactive above  
388 the threshold for SARS-CoV-2 spike protein IgM, and EPICC spike geometric IgM levels were  
389 2612 MFI (1684-2775 95% CI) and JMS spike geometric IgM levels were 11,595 MFI (9438-  
390 14,244 95% CI) (Fig. S3C). EPICC sera tested represent a cohort of 62% outpatients, and  
391 differences in detectable IgM levels between EPICC and JMS are probably reflections of  
392 COVID-19 clinical outcomes that separate cohort. The SARS-CoV-2 spike reactive IgM  
393 detection sensitivity was lower than IgG, with performance analysis conducted with serum  
394 samples collected  $\geq 7$  days post-symptom onset, sensitivity= 73.33% (65.51%-80.22% CI),  
395 specificity= 100.00% (95.70-100.00%), PPV= 100.00 and NPV= 98.62% (98.20%-98.95%)  
396 (Table S1).The temporal window to capture SARS-CoV-2 IgM was shorter than IgG, and as  
397 serum samples included in  $\beta$ -CoV MMIA performance analysis ranged from 10 – 60 dpso, lower  
398 IgM sensitivity is further driven by outpatient enrollments in the EPICC protocol with an average  
399 28 dpso that were IgG positive, but IgM negative (Table S2).

400

#### 401 *SARS-2/HCoV spike MMIA*

402 The interplay of pre-existing HCoV spike-specific antibodies and COVID-19 outcomes,  
403 as well as post vaccine responses, remains a critical question. As such, we also validated a  
404 SARS-2/HCoV spike MMIA strategy that can simultaneously measure antibodies to SARS-CoV-  
405 2 and all four seasonal HCoVs. To validate this MMIA strategy, we utilized EPICC serum  
406 samples (n= 148) from SARS-CoV-2 PCR-positive participants collected 7 – 60 dpso (median=  
407 35, IQR= 23). Again, we detected no SARS-CoV-2 S-2P IgG positives in ARIC sera, and  
408 geometric mean IgG levels were 21,487 MFI (19,568-23,584 CI) and 30,871 MFI (30,403-  
409 31,346 CI) from EPICC and JMS serum samples, respectively (Fig. 3A). In addition to serum



410 samples collected at hospitals, the EPICC protocol provides at-home blood collection of  
411 capillary blood samples as DBS for longitudinal serology. Of additional importance, we validated  
412 paired DBS IgG against serum collected by serum separator tubes (SST) and observed a  
413 significant and strong linear correlation of SARS-CoV-2 MFI derived from DBS and SST  
414 collected blood specimens (Fig. 3B). Reports have demonstrated anti-S glycoprotein IgG  
415 seroconversion between 3 and 14 dpi (41, 48-50), to further assess the MMIA strategy,  
416 sensitivity for the SARS-2/HCoV MMIA was measured within an early and narrow range of  
417 EPICC and JMS blood specimen collection, 7-28 dpso. SARS-2/HCoV spike MMIA assay  
418 performance was, sensitivity= 94.4% (86.4%-98.5% CI), specificity= 100.0% (95.7%-  
419 100.0% CI), PPV= 100.0% and NPV= 99.7% (99.3%-99.9% CI) (Table 5). As previously  
420 seen with the  $\beta$ -CoV assay, inclusion of HCoV spike improves specificity for SARS-CoV-2; both  
421  $\beta$ -CoV and SARS-2/HCoV MMIA have near identical upper threshold cutoff values, 4910 MFI  
422 and 4774 MFI, thus the inclusion of HCoV-HKU1 and HCoV-OC43 spike led to improvements in  
423 specificity.

424

425

426

427

428

429

430

431

432

433

434

435

436


437

438

439

440

441



442 **Figure 3. SARS-2/HCoV MMIA detection of SARS-CoV-2 IgG in blood specimens. (A)**

443 Serum samples were screened with a SARS-2/HCoV spike protein MMIA and reactivity to  
444 SARS-CoV-2 spike is shown; shaded grey bar indicates the threshold cutoff for IgG positivity.

445 **(B)** Paired blood specimens (n= 22) collected from capillary blood as a dried blood spot (DBS)  
446 and serum collected by serum separator tubes (SST) were tested with the SARS-2/HCoV spike  
447 protein MMIA; SARS-CoV-2 spike reactive IgG MFI is indicated on x- and y-axes.

448

449

450

451

452

453

454

455

456

457

458

459

460

461 *COVID-19 subject antibody reactivity with zoonotic and endemic coronaviruses*

462           Next, we investigated SARS-CoV-2 *de novo* IgG antibody cross-reactivity with SARS-  
463 CoV and MERS-CoV spike proteins. Threshold cutoffs for SARS-CoV and MERS-CoV spike  
464 reactive IgG were similarly set with ARIC sera as detailed for SARS-CoV-2 spike (Fig. 4A). An  
465 indeterminate range (3840 – 4910 MFI) for positive/negative IgG reactivity was established with  
466 SARS-CoV-2, SARS-CoV and MERS-CoV spike protein reactive IgG MFI and 4910 MFI  
467 represents the threshold for positivity. We compared levels of SARS-CoV and MERS-CoV  
468 reactive IgG in SARS-CoV-2 PCR positive subjects. SARS-CoV and MERS-CoV S glycoprotein  
469 share 82% and 50% homology, respectively, with SARS-CoV-2 S glycoprotein (37). A  
470 significant level of cross-reactive antibodies to SARS-CoV and MERS-CoV were observed in  
471 SARS-CoV-2 PCR positive and IgG positive EPICC and JMS cohort sera, but not SARS-CoV-2  
472 naïve ARIC sera (Fig. 4B). The geometric mean IgG MFI levels of SARS-CoV reactive IgG in  
473 EPICC and JMS were 4007 (3422 – 4693 CI) and 9307 (7423 – 11,669 CI), respectively; and  
474 the geometric mean IgG MFI levels of MERS-CoV reactive IgG in EPICC and JMS were 4255  
475 (3517 – 5173 CI) and 8307 (6436 – 10,722 CI), respectively.

476

477

478

479

480

481


482

483

484

485

486



487

488 **Figure 4. SARS-CoV and MERS-CoV IgG increases after SARS-CoV-2 infection. (A)** 99.7%  
489 probability distribution of ARIC HCoV PCR+ convalescent serum samples (n= 43) reactive with  
490 SARS-CoV (SARS-1) and MERS-CoV (MERS) spike; a dashed line and solid line indicates the  
491 SARS-CoV and MERS-CoV spike protein threshold cutoff values, respectively. **(B)** Sera from  
492 SARS-CoV-2 positive EPICC and JMS cohorts were tested in a  $\beta$ -CoV MMIA for IgG reactivity  
493 to SARS-CoV and MERS-CoV spike, a shaded grey line indicates the threshold cutoff for IgG  
494 positivity; error bars indicate the geometric mean and 95% confidence intervals; unpaired Mann-  
495 Whitney t-tests of EPICC and JMS compared to ARIC, \*\*\*\*  $P$ -values= < 0.0001.

496

497

498

499

500

501

502

503           In the absence of HCoV naïve human cohort, we turned to SARS-CoV-2 non-human  
504 primates (NHP) model to inform the stimulation of HCoV cross-reactive antibodies. NHP had no  
505 evidence of *de novo* IgG reactivity with HCoV-HKU1 and HCoV-OC43 spike proteins after  
506 SARS-CoV-2 challenge and seroconversion (Fig. 5A). We extrapolated the 99.7% indeterminate  
507 range of SARS-CoV, SARS-CoV-2 and MERS-CoV spike protein reactive IgG as a cutoff for  
508 HCoV reactive antibodies (Fig. 4A). We found that IgG reactivity with HCoV spike proteins in the  
509 SARS-CoV-2 PCR positive patient serum samples were significantly higher than those in  
510 SARS-CoV-2 naïve ARIC cohort. We found significant geometric mean IgG increases of HCoV-  
511 OC43, 26,518 (25,920-27,131 CI) and 29,454 (28,759-30,167 CI) in EPICC and JMS cohorts,  
512 respectively; HCoV-HKU1 geometric mean IgG levels in EPICC and JMS cohorts were 15,739  
513 (14,693-16,859 CI) and 19,360 (17,027-22,012 CI), respectively (Fig. 5B). Furthermore, we  
514 detected a significant increase in IgG-reactive with HCoV-NL63 associated with SARS-CoV-2  
515 infection in EPICC and JMS cohorts; a significant increase in HCoV-229E IgG was detected in  
516 JMS sera (Figure 5C).

517

518

519

520

521

522

523

524


525

526

527

528

529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554



**Figure 5. SARS-CoV-2 infection is associated with rises in HCoV antibody levels.**

(A) Serum samples collected 21 dpi from SARS-CoV-2 challenged non-human primates (n= 4) and tested in two independent experiments performed in technical duplicates with a SARS-2/HCoV spike protein MMIA; error bars represent mean±SD. IgG reactivity with seasonal HCoV, -HKU1 and -OC43 (β-CoVs) (B) and -229E and -NL63 (α-CoVs) (C), spike proteins were tested with a SARS-2/HCoV spike MMIA. Error bars indicate the geometric mean and 95% CI, IgG levels were compared by unpaired t-tests with Welch’s correction of EPICCC and JMS compared to ARIC, \*\*\*\* *P*-values= < 0.0001.

## 555 **DISCUSSION**

556           In this study, we have demonstrated that use of a multiplex microsphere-based  
557 immunoassay (MMIA) built using Luminex xMAP-based technology in which individual  
558 microspheres are bound to pre-fusion stabilized S glycoprotein trimers of SARS-CoV-2 and the  
559 seasonal endemic HCoV-229E enables sensitive and specific detection of SARS-CoV-2 IgG  
560 antibodies. Our SARS-CoV-2 spike-based MMIA strategies have sensitivities ranging 94 – 99 %  
561 as early as 7 – 10 days after symptom onset in PCR-confirmed cases of SARS-CoV-2 infection  
562 and 100% specificity for SARS-CoV-2 IgG, comparable with several other EUA serology tests  
563 (6). Conserved epitopes present in the prefusion stabilized native-like trimeric S glycoprotein  
564 oligomers (spike protein) are the likely major factor in the observed cross reactions between the  
565 coronavirus S glycoproteins, affecting specificity for some serology assays. By using HCoV-  
566 HKU1 and HCoV-OC43 spike proteins to capture pre-existing antibodies that would be cross-  
567 reactive with SARS-CoV-2 spike, the assay had a 100% specificity for SARS-CoV-2 serology.  
568 Importantly, the ability to simultaneously capture SARS-CoV-2 spike and NP-specific antibodies  
569 within a single assay will facilitate high-throughput approaches for differentiating antibody  
570 responses between SARS-CoV-2 natural infections and vaccinations.

571           The magnitude of the antibody response to SARS-CoV-2 infection has been associated  
572 with COVID-19 severity (51). This was apparent in our validation tests as geometric mean IgG  
573 levels were consistently elevated in sera from the JMS cohort, comprised of all hospitalized  
574 patients, whereas sera from the EPICC cohort had lower geometric mean IgG to SARS-CoV-2  
575 antigens, of which the majority of EPICC study participants were outpatients. Interestingly,  
576 geometric mean IgG level, 20,542 MFI (18,806-22,440 CI) to SARS-CoV-2 spike determined by  
577 testing with the  $\beta$ -CoV MMIA was lower than the geometric mean IgG levels spike, 25,226 MFI  
578 (23,703-27,490 CI) in the SARS-2 spike/NP MMIA. One possibility is that in the  $\beta$ -CoV MMIA,  
579 inclusion of spike and RBD which represent overlapping epitopes leads to competition for  
580 antibodies, decreasing overall MFI levels to either S glycoprotein antigen individually. The effect

581 of this binding competition could negatively affect durability studies of longitudinal samples  
582 when concentrations of circulating SARS-CoV-2 sera IgG begins to wane. Whereas establishing  
583 the SARS-CoV-2 spike protein and NP MMIA will have utility for the future differentiation  
584 between antibody responses to SARS-CoV-2 vaccination and natural infection induced antibody  
585 responses, with some inherent limitations to sensitivity and specificity.

586       Of additional importance, the MMIA approach demonstrated *de novo* IgG cross-reactivity  
587 with SARS-CoV and MERS-CoV in the SARS-CoV-2 PCR+/IgG+ EPICC and JMS cohorts  
588 compared with archival sera (ARIC). The EPICC geometric mean IgG levels reactive with  
589 SARS-CoV spike were near the indeterminate range of positivity, suggesting that significant  
590 rises in IgG levels after SARS-CoV-2 are driven by a subset of subjects that develop specific B  
591 cell repertoires that can be cross-reactive with SARS-CoV. A higher geometric mean IgG level  
592 to SARS-CoV and MERS-CoV were detected in JMS sera, which includes all hospitalized  
593 patients and suggests that induction of cross-reactivity is associated with COVID-19 severity.  
594 Conserved cross-neutralizing epitopes between SARS-CoV and SARS-CoV-2 S glycoproteins  
595 have been identified (52, 53), whether SARS-CoV-2 induced *de novo* IgG antibody responses to  
596 SARS-CoV and MERS-CoV spike proteins detected with this MMIA strategy are retained after  
597 affinity maturation, or are cross-neutralizing requires further investigation. The induction of  
598 cross-reactive SARS-CoV, SARS-CoV-2 and MERS-CoV antibodies further demonstrates that  
599 shared spike proteins epitopes exist and that rational-vaccine designs may be able to develop  
600 pan-zoonotic coronavirus vaccines.

601       Here, we observed increases in seasonal HCoV spike reactive IgG antibodies in SARS-  
602 CoV-2 positive cohort. SARS-CoV-2 has been shown to stimulate OC43 memory B cells  
603 through conserved epitopes in the SARS-CoV-2 S glycoprotein S2 subunit and serum samples  
604 from subjects with recent HCoV infection contain SARS-CoV-2 cross-reactive but not cross-  
605 neutralizing antibodies (54). As *de novo* IgG cross-reactivity with HCoV-HKU1 and HCoV-OC43  
606 spike protein was not observed in SARS-CoV-2 challenged NHPs (Figure 5A), the presence of



607 prior humoral memory to seasonal HCoV appears necessary to drive cross-reactivity. Overall,  
608 the OC43 S glycoprotein only shares 30 to 40% amino acid sequence identity/similarity with  
609 SARS-CoV-2 S glycoprotein (37). The S1 subunit, wherein resides the RBD, has more  
610 sequence variance among OC43 and SARS-CoV-2, in contrast to the S2 subunit heptad repeat  
611 regions where amino acid sequence similarity is between 50 to 75%. It would seem unlikely that  
612 a SARS-CoV-2 *de novo* IgG response would result in cross-reactive antibodies that would bind  
613 at immunoassay saturation to distantly-related seasonal  $\beta$ -CoVs. However, we did observe  
614 increases in HCoV-NL63 spike reactive antibodies EPICC and JMS cohorts, suggestive that  
615 SARS-CoV-2 infection and the subsequent heightened inflammatory state can induce a humoral  
616 response with enough antibody diversity capable of binding to distantly-related human  $\alpha$ -CoVs.  
617 It will be important to expand on this observation with larger numbers of subjects in different age  
618 groups to evaluate the extent of SARS-CoV-2 stimulated seasonal HCoV memory responses.

619 Other, preliminary evidence has estimated a negative relationship between HKU1 and  
620 OC43 back-boosted responses and the generation of SARS-CoV-2 neutralizing antibodies (55),  
621 implying that in some subjects OC43 immune imprinting may have similar effects akin to  
622 immunological imprinting, antigenic epitope masking and/or *original antigenic sin* (56, 57).  
623 Whether HCoV immune imprinting has any association with clinical outcomes or SARS-CoV-2  
624 antibody longevity requires further investigation. Back-boosting stimulation of a cross-reactive  
625 memory response might also explain cases of synchronous SARS-CoV-2 IgM and IgG  
626 seroconversion and IgG seroconversion prior to IgM (58). To our knowledge there is no  
627 evidence that HCoV-induced antibodies promote clinical protection in SARS-CoV-2 infected  
628 individuals. The vast majority of the SARS-CoV-2 confirmed participants in these studies had  
629 high levels of HCoV-OC43 IgG; however, they were also seeking treatment for mild to  
630 moderate/severe COVID-19 which requires further investigation. Larger, prospective,  
631 longitudinal observational studies in which serum samples are obtained before infection may  
632 ultimately be required to definitively determine if HCoV-induced antibodies confer any protection

633 against COVID-19 and if the presence of HCoV memory affects the longevity and development  
634 of a protective SARS-CoV-2 humoral response.

635

#### 636 **DECLARATIONS**

637 These research protocols, IDCRP-085, IDCRP-045 and CAMP-NYC, were approved by the  
638 USU IRB. The data that support the findings of this study are available from the corresponding  
639 author(s) upon reasonable request.

640

#### 641 **ETHICS STATEMENT**

642 The referenced human subjects protocols (IDCRP-045, IDCRP-085, and CAMP-NYC)  
643 were approved by the Uniformed Services University Institutional Review Board and  
644 participating sites. All subjects provided written or verbal informed consent using  
645 approved documents and procedures; the consent forms include clauses allowing use  
646 of specimens for investigations including those conducted in this study.

647

#### 648 **CONFLICT OF INTEREST**

649 None of the authors have any conflicts of interest of relevance to disclose.

650

#### 651 **DISCLAIMER**

652 The contents of this publication are the sole responsibility of the author(s) and do  
653 not necessarily reflect the views, opinions, or policies of the Uniformed Services University  
654 (USU), the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF),  
655 National Institutes of Health or the Department of Health and Human Services, Brooke Army  
656 Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon  
657 General, the US Department of Defense (DoD), the Departments of the Air Force, Army or

658 Navy, or the U.S. Government. Mention of trade names, commercial products, or organization  
659 does not imply endorsement by the U.S. Government. A number of the co-authors are military  
660 service members (or employees of the U.S. Government). This work was prepared as part of  
661 their official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not  
662 available for any work of the United States Government.' Title 17 U.S.C. §101 defines a U.S.  
663 Government work as a work prepared by a military service member or employee of the U.S.  
664 Government as part of that person's official duties.

665

## 666 **FUNDING**

667 This project has been funded by the Defense Health Program, U.S. DoD, under award  
668 HU0001190002 and the National Institute of Allergy and Infectious Diseases, National Institutes  
669 of Health, under Inter-Agency Agreement Y1-AI-5072. This project has been funded in part with  
670 Federal funds from the National Cancer Institute, National Institutes of Health, under contract  
671 number HHSN261200800001E. VJM and EdW are supported by the Intramural Research  
672 Program of the National Institutes of Allergy and Infectious Diseases.

673

## 674 **ACKNOWLEDGEMENTS**

675 We thank Kelly Snead, Vanessa Wall, John-Paul Denson, Simon Messing, and William  
676 Gillette (Protein Expression Lab, FNCLR) for excellent technical assistance. We also  
677 thank Kathleen Pratt (Department of Medicine, USUHS) for assistance with CAMP-NYC  
678 sample acquisition.

679

680

681

682

683 **REFERENCES**

- 684 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al  
685 Khalili S, Simonsen L. 2020. Comparing SARS-CoV-2 with SARS-CoV and influenza  
686 pandemics. *Lancet Infect Dis* 20:e238-e244.
- 687 2. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J,  
688 Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T. 2020. Genome Composition and  
689 Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host*  
690 *Microbe* 27:325-328.
- 691 3. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S,  
692 Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire  
693 EO, Smith DM, Weiskopf D, Sette A, Crotty S. 2020. Immunological memory to SARS-  
694 CoV-2 assessed for up to eight months after infection. *bioRxiv*  
695 doi:10.1101/2020.11.15.383323.
- 696 4. Röltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, Hunter M, Wang H,  
697 Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham  
698 TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL,  
699 Wang TT, Narasimhan B, Gombar S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA,  
700 Boyd SD. 2020. Defining the features and duration of antibody responses to SARS-CoV-  
701 2 infection associated with disease severity and outcome. *Sci Immunol* 5.
- 702 5. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof  
703 GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB.  
704 2020. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus  
705 2 Antibody Responses and Their Relationship to Disease Severity. *Clinical Infectious*  
706 *Diseases* 72:301-308.
- 707 6. F.D.A US. (2021, January 8) EUA authorized serology test performance.
- 708 7. Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. 2020. The  
709 molecular virology of Coronaviruses. *J Biol Chem* doi:10.1074/jbc.REV120.013930.
- 710 8. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA,  
711 Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR,  
712 Chappell JD, Graham BS, Ward AB, McLellan JS. 2017. Immunogenicity and structures  
713 of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A*  
714 114:E7348-e7357.
- 715 9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS,  
716 McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion  
717 conformation. *Science* 367:1260-1263.
- 718 10. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,  
719 Jiang K, Arunkumar GA, Jurczynszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G,  
720 Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH, Cunningham-  
721 Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska  
722 K, Vapalahti O, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect  
723 SARS-CoV-2 seroconversion in humans. *Nat Med* 26:1033-1036.
- 724 11. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, Frank P, Denson JP, Hong  
725 M, Gulten G, Sadtler K, Messing S, Gillette W. 2020. Optimizing high-yield production of  
726 SARS-CoV-2 soluble spike trimers for serology assays. *Protein Expr Purif* 174:105686.
- 727 12. Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, Wang J,  
728 Hicks J, Mehalko J, Travers J, Drew M, Pauly K, Spathies J, Ngo T, Adusei KM,  
729 Karkanitsa M, Croker JA, Li Y, Graubard BI, Czajkowski L, Belliveau O, Chairez C,  
730 Snead K, Frank P, Shunmugavel A, Han A, Giurgea LT, Rosas LA, Bean R, Athota R,  
731 Cervantes-Medina A, Gouzoulis M, Heffelfinger B, Valenti S, Caldararo R, Kolberg MM,  
732 Kelly A, Simon R, Shafiq S, Wall V, Reed S, Ford EW, Lokwani R, Denson JP, Messing

- 733 S, Michael SG, Gillette W, Kimberly RP, Reis SE, Hall MD, et al. 2021. Mapping a  
734 Pandemic: SARS-CoV-2 Seropositivity in the United States. medRxiv  
735 doi:10.1101/2021.01.27.21250570.
- 736 13. Klumpp-Thomas C, Kalish H, Drew M, Hunsberger S, Snead K, Fay MP, Mehalko J,  
737 Shunmugavel A, Wall V, Frank P, Denson JP, Hong M, Gulten G, Messing S, Hicks J,  
738 Michael S, Gillette W, Hall MD, Memoli MJ, Esposito D, Sadtler K. 2021. Standardization  
739 of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-  
740 home blood sampling. *Nat Commun* 12:113.
- 741 14. Okba NMA, Müller M, Li W, Wang C, GeurtsvanKessel C, Corman V, Lamers M,  
742 Sikkema R, de Bruin E, Chandler F, Yazdanpanah Y, Le Hingrat Q, Descamps D,  
743 Houhou-Fidouh N, Reusken CBEM, Bosch B-J, Drosten C, Koopmans MPG, Haagmans  
744 B. 2020. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody  
745 Responses in Coronavirus Disease Patients. *Emerging Infectious Disease journal*  
746 26:1478.
- 747 15. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ,  
748 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Roupheal  
749 N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz  
750 J, Baric RS, de Silva AM. 2020. The receptor-binding domain of the viral spike protein is  
751 an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.  
752 *Science Immunology* 5:eabc8413.
- 753 16. Klumpp-Thomas C, Kalish H, Drew M, Hunsberger S, Snead K, Fay MP, Mehalko J,  
754 Shunmugavel A, Wall V, Frank P, Denson JP, Hong M, Gulten G, Messing S, Hicks J,  
755 Michael S, Gillette W, Hall MD, Memoli M, Esposito D, Sadtler K. 2020. Standardization  
756 of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic  
757 using clinical and at-home blood sampling. medRxiv doi:10.1101/2020.05.21.20109280.
- 758 17. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S,  
759 Lu H, Wen Y, Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a  
760 COVID-19 recovered patient cohort and their implications. medRxiv  
761 doi:10.1101/2020.03.30.20047365:2020.03.30.20047365.
- 762 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR,  
763 Tan YJ, Foo R, Yi Y, Lye DC, Anderson DE, Wang LF. 2020. A SARS-CoV-2 surrogate  
764 virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-  
765 protein interaction. *Nat Biotechnol* 38:1073-1078.
- 766 19. Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson M-A,  
767 Mortgat L, Duysburgh E, Desombere I, Jansens H, Van Esbroeck M, Ariën KK. 2021.  
768 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody  
769 detection in severe and mild COVID-19 cases using a Luminex bead-based assay.  
770 *Journal of Virological Methods* 288:114025.
- 771 20. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, Parker  
772 MM, John Leung SY, Morne JE, Greene D, Holtgrave DR, Hofer D, Kumar J, Udo T,  
773 Hutton B, Zucker HA. 2020. Cumulative incidence and diagnosis of SARS-CoV-2  
774 infection in New York. *Ann Epidemiol* 48:23-29.e4.
- 775 21. Norman M, Gilboa T, Ogata AF, Maley AM, Cohen L, Busch EL, Lazarovits R, Mao C-P,  
776 Cai Y, Zhang J, Feldman JE, Hauser BM, Caradonna TM, Chen B, Schmidt AG, Alter G,  
777 Charles RC, Ryan ET, Walt DR. 2020. Ultrasensitive high-resolution profiling of early  
778 seroconversion in patients with COVID-19. *Nature Biomedical Engineering*  
779 doi:10.1038/s41551-020-00611-x.
- 780 22. Bray RA, Lee JH, Brescia P, Kumar D, Nong T, Shih R, Woodle ES, Maltzman JS,  
781 Gebel HM. 2021. Development and Validation of a Multiplex, Bead-based Assay to  
782 Detect Antibodies Directed Against SARS-CoV-2 Proteins. *Transplantation* 105:79-89.

- 783 23. Drouot L, Hantz S, Jouen F, Velay A, Lamia B, Veber B, Sibilia J, Lotellier M, Candon S,  
784 Alain S, Fafi-Kremer S, Boyer O. 2020. Evaluation of Humoral Immunity to SARS-CoV-2:  
785 Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay. *Front*  
786 *Microbiol* 11:603931.
- 787 24. Ayoub A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E,  
788 Peeters M. 2017. Development of a Sensitive and Specific Serological Assay Based on  
789 Luminex Technology for Detection of Antibodies to Zaire Ebola Virus. *J Clin Microbiol*  
790 55:165-176.
- 791 25. Powell RL, Ouellette I, Lindsay RW, Parks CL, King CR, McDermott AB, Morrow G.  
792 2013. A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-  
793 Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from  
794 Rhesus Macaques Infected with SIVmac239. *Biores Open Access* 2:171-8.
- 795 26. Satterly NG, Voorhees MA, Ames AD, Schoepp RJ. 2017. Comparison of MagPix  
796 Assays and Enzyme-Linked Immunosorbent Assay for Detection of Hemorrhagic Fever  
797 Viruses. *J Clin Microbiol* 55:68-78.
- 798 27. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S, Beveridge A, Bibi  
799 S, Blackwell L, Borak M, Bown A, Brooks T, Burgess-Brown NA, Camara S, Catton M,  
800 Chau KK, Christott T, Clutterbuck E, Coker J, Cornall RJ, Cox S, Crawford-Jones D,  
801 Crook DW, D'Arcangelo S, Dejnirattasai W, Dequaire JMM, Dimitriadis S, Dingle KE,  
802 Doherty G, Dold C, Dong T, Dunachie SJ, Ebner D, Emmenegger M, Espinosa A, Eyre  
803 DW, Fairhead R, Fassih S, Feehily C, Felle S, Fernandez-Cid A, Fernandez Mendoza  
804 M, Foord TH, Fordwoh T, Fox McKee D, Frater J, Gallardo Sanchez V, Gent N,  
805 Georgiou D, Groves CJ, et al. 2020. Performance characteristics of five immunoassays  
806 for SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet Infectious*  
807 *Diseases* 20:1390-1400.
- 808 28. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,  
809 Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,  
810 Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,  
811 Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B,  
812 Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T. 2021. Efficacy and Safety of the  
813 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 384:403-416.
- 814 29. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez  
815 Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P,  
816 Kalina WV, Cooper D, Frenck RW, Jr., Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal  
817 S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. Safety  
818 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603-2615.
- 819 30. Clifton GT, Pati R, Krammer F, Laing ED, Broder CC, Mendu DR, Chen HW, Sugiharto  
820 VA, Simons MP, Kang AD, Stadlbauer D, Pratt KC, Bandera BC, Fritz DK, Millar EV,  
821 Burgess TH, Chung KK. 2021. SARS-CoV-2 infection risk among active duty military  
822 members deployed to a New York City field hospital in support of the COVID-19  
823 pandemic response. *MMWR in press*
- 824 31. Lalani T, Lee TK, Laing ED, Ritter A, Cooper E, Lee M, Baker M, Baldino T, McAdoo T,  
825 Phogat S, Samuels E, Nguyen H, Broder CC, Epsi N, Richard SA, Warkentien TE, Millar  
826 EV, Burgess T, Kronmann KC. 2021. SARS-CoV-2 Infections and Serologic Responses  
827 Among Military Personnel Deployed on the USNS COMFORT to New York City During  
828 the COVID-19 Pandemic. *Open Forum Infect Dis* 8:ofaa654.
- 829 32. Coles C, Millar EV, Burgess T, Ottolini MG. 2019. The Acute Respiratory Infection  
830 Consortium: A Multi-Site, Multi-Disciplinary Clinical Research Network in the Department  
831 of Defense. *Mil Med* 184:44-50.

- 832 33. Kozak R, Prost K, Yip L, Williams V, Leis JA, Mubareka S. 2020. Severity of coronavirus  
833 respiratory tract infections in adults admitted to acute care in Toronto, Ontario. *J Clin*  
834 *Viro* 126:104338.
- 835 34. Nickbakhsh S, Thorburn F, B VONW, Mc MJ, Gunson RN, Murcia PR. 2016. Extensive  
836 multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory  
837 infections. *Epidemiol Infect* 144:2064-76.
- 838 35. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. 2016.  
839 *Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends*  
840 *Microbiol* 24:490-502.
- 841 36. Freeman B, Lester S, Mills L, Rasheed MAU, Moyo S, Abiona O, Hutchinson GB,  
842 Morales-Betoulle M, Krapinunaya I, Gibbons A, Chiang C-F, Cannon D, Klena J,  
843 Johnson JA, Owen SM, Graham BS, Corbett KS, Thornburg NJ. 2020. Validation of a  
844 SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance.  
845 *bioRxiv : the preprint server for biology*  
846 doi:10.1101/2020.04.24.057323;2020.04.24.057323.
- 847 37. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead K,  
848 Drew M, Corbett K, Graham B, Hall MD, Esposito D, Sadtler K. 2020. Serologic cross-  
849 reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. *medRxiv*  
850 doi:10.1101/2020.06.22.20137695.
- 851 38. Esposito D, Mehalko J, Drew M, Snead K, Wall V, Taylor T, Frank P, Denson JP, Hong  
852 M, Gulten G, Sadtler K, Messing S, Gillette W. 2020. Optimizing high-yield production of  
853 SARS-CoV-2 soluble spike trimers for serology assays. *bioRxiv*  
854 doi:10.1101/2020.05.27.120204.
- 855 39. Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA, Corbett KS,  
856 Graham BS, McLellan JS, Ward AB. 2018. Stabilized coronavirus spikes are resistant to  
857 conformational changes induced by receptor recognition or proteolysis. *Sci Rep*  
858 8:15701.
- 859 40. Bouvier M, Chen WJ, Arnold JC, Fairchok MP, Danaher PJ, Lalani T, Malone L, Mor D,  
860 Ridore M, Burgess TH, Millar EV. 2018. Species-specific clinical characteristics of  
861 human coronavirus infection among otherwise healthy adolescents and adults. *Influenza*  
862 *Other Respir Viruses* 12:299-303.
- 863 41. Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Pérez-Pérez L, Schulz J,  
864 Meade-White K, Okumura A, Callison J, Brumbaugh B, Avanzato VA, Rosenke R,  
865 Hanley PW, Saturday G, Scott D, Fischer ER, de Wit E. 2020. Respiratory disease in  
866 rhesus macaques inoculated with SARS-CoV-2. *Nature* doi:10.1038/s41586-020-2324-  
867 7.
- 868 42. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C,  
869 Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P,  
870 Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin  
871 GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR,  
872 Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C,  
873 Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin  
874 SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. 2020. Preexisting and de novo  
875 humoral immunity to SARS-CoV-2 in humans. *Science* 370:1339-1343.
- 876 43. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin W-H, Wontakal S, Szabo PA, Wells  
877 SB, Dogra P, Gray J, Idzikowski E, Stelitano D, Bovier FT, Davis-Porada J, Matsumoto  
878 R, Poon MML, Chait M, Mathieu C, Horvat B, Decimo D, Hudson KE, Zotti FD, Bitan ZC,  
879 La Carpia F, Ferrara SA, Mace E, Milner J, Moscona A, Hod E, Porotto M, Farber DL.  
880 2021. Distinct antibody responses to SARS-CoV-2 in children and adults across the  
881 COVID-19 clinical spectrum. *Nature Immunology* 22:25-31.

- 882 44. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL,  
883 Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich  
884 TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G.  
885 2020. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. *Immunity*  
886 53:524-532.e4.
- 887 45. Liu L, Liu W, Zheng Y, Jiang X, Kou G, Ding J, Wang Q, Huang Q, Ding Y, Ni W, Wu W,  
888 Tang S, Tan L, Hu Z, Xu W, Zhang Y, Zhang B, Tang Z, Zhang X, Li H, Rao Z, Jiang H,  
889 Ren X, Wang S, Zheng S. 2020. A preliminary study on serological assay for severe  
890 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital  
891 patients. *Microbes and infection* 22:206-211.
- 892 46. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, Yu F, Ge S-X, Zou Q-D, Yuan Q, Lin S,  
893 Hong C-M, Yao X-Y, Zhang X-J, Wu D-H, Zhou G-L, Hou W-H, Li T-T, Zhang Y-L,  
894 Zhang S-Y, Fan J, Zhang J, Xia N-S, Chen Y. 2020. Serology characteristics of SARS-  
895 CoV-2 infection after exposure and post-symptom onset. *European Respiratory Journal*  
896 56:2000763.
- 897 47. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao  
898 Y, Zhang L, Han L, Dang S, Xu Y, Yang Q-W, Xu S-Y, Zhu H-D, Xu Y-C, Jin Q, Sharma  
899 L, Wang L, Wang J. 2020. Profiling Early Humoral Response to Diagnose Novel  
900 Coronavirus Disease (COVID-19). *Clinical Infectious Diseases* 71:778-785.
- 901 48. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F,  
902 Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao  
903 L, Liu X, Wei Q, Qin C. 2020. Primary exposure to SARS-CoV-2 protects against  
904 reinfection in rhesus macaques. *Science* 369:818-823.
- 905 49. Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, Kuang D, Yang M, Yang J, Ma C, Xu J,  
906 Qian X, Li H, Zhao S, Li J, Wang H, Long H, Zhou J, Luo F, Ding K, Wu D, Zhang Y,  
907 Dong Y, Liu Y, Zheng Y, Lin X, Jiao L, Zheng H, Dai Q, Sun Q, Hu Y, Ke C, Liu H, Peng  
908 X. 2020. Comparison of nonhuman primates identified the suitable model for COVID-19.  
909 *Signal Transduct Target Ther* 5:157.
- 910 50. Shan C, Yao YF, Yang XL, Zhou YW, Gao G, Peng Y, Yang L, Hu X, Xiong J, Jiang RD,  
911 Zhang HJ, Gao XX, Peng C, Min J, Chen Y, Si HR, Wu J, Zhou P, Wang YY, Wei HP,  
912 Pang W, Hu ZF, Lv LB, Zheng YT, Shi ZL, Yuan ZM. 2020. Infection with novel  
913 coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. *Cell Res* 30:670-  
914 677.
- 915 51. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D,  
916 Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus  
917 J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Ollmann Saphire E, Smith DM,  
918 Sette A, Crotty S. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute  
919 COVID-19 and Associations with Age and Disease Severity. *Cell* 183:996-1012.e19.
- 920 52. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-  
921 Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino B, Minola A, Zatta  
922 F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF,  
923 Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda AF, Biggiogero M, Tarkowski M,  
924 Pizzuto MS, Cameroni E, Havenar-Daughton C, Smithey M, Hong D, Lepori V, Albanese  
925 E, Ceschi A, Bernasconi E, Elzi L, Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink  
926 K, Virgin HW, Lanzavecchia A, Corti D, Veesler D. 2020. Mapping Neutralizing and  
927 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by  
928 Structure-Guided High-Resolution Serology. *Cell* 183:1024-1042.e21.
- 929 53. Zang J, Gu C, Zhou B, Zhang C, Yang Y, Xu S, Bai L, Zhang R, Deng Q, Yuan Z, Tang  
930 H, Qu D, Lavillette D, Xie Y, Huang Z. 2020. Immunization with the receptor-binding  
931 domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-  
932 CoV without antibody-dependent enhancement. *Cell Discov* 6:61.



- 933 54. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatzioannou T, Bieniasz P.  
934 2020. Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from  
935 individuals with recent seasonal coronavirus infection. *Clin Infect Dis*  
936 doi:10.1093/cid/ciaa1803.
- 937 55. Aydililo T, Rombauts A, Stadlbauer D, Aslam S, Abelenda-Alonso G, Escalera A, Amanat  
938 F, Jiang K, Krammer F, Carratala J, García-Sastre A. 2020. Antibody Immunological  
939 Imprinting on COVID-19 Patients. *medRxiv*  
940 doi:10.1101/2020.10.14.20212662:2020.10.14.20212662.
- 941 56. Zarnitsyna VI, Ellebedy AH, Davis C, Jacob J, Ahmed R, Antia R. 2015. Masking of  
942 antigenic epitopes by antibodies shapes the humoral immune response to influenza.  
943 *Philos Trans R Soc Lond B Biol Sci* 370.
- 944 57. Kelvin AA, Zambon M. 2019. Influenza imprinting in childhood and the influence on  
945 vaccine response later in life. *Euro Surveill* 24.
- 946 58. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K,  
947 Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. 2020. Clinical and  
948 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 26:1200-  
949 1204.

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967 **TABLES**

968 **Table 1. Antigen composition of each MMIA**

MMIA variation	Virus	Antigen
$\beta$ -CoV	SARS-CoV-2	spike
		RBD
	SARS-CoV	spike
	MERS-CoV	spike
	HCoV-HKU1	spike
	HCoV-OC43	spike
SARS-2/HCoV	SARS-CoV-2	spike
		HCoV-HKU1
	HCoV-OC43	spike
	HCoV-229E	spike
	HCoV-NL63	spike
SARS-2 spike/NP	SARS-CoV-2	spike
		NP

969

970 **Table 2. MFI threshold cutoffs for SARS-CoV-2 positive IgG**

MMIA variation	antigen	99.7% (ARIC)	ROC (EPICC)
$\beta$ -CoV	spike	4910	4853
	RBD	4666	4622
SARS-2/HCoV	spike	4774	4144
SARS-2 spike/NP	NP	6649	6372

971

972 **Table 3.  $\beta$ -CoV MMIA performance**

		SARS-CoV-2 PCR Status/Archival Sera			
		Positive <sup>1</sup>	Negative	Total	
SARS-CoV-2 spike IgG Antibody Test	Positive	149	0	149	
	Negative <sup>2</sup>	1	84	85	
	Total	150	84	234	
	Sensitivity		99.33		
	Specificity		100%		
		Positive	Negative	Total	
SARS-CoV-2 RBD IgG Antibody Test	Positive	144	3	147	
	Negative	6	81	87	
	Total	150	84	234	
	Sensitivity		96.00%		
	Specificity		96.43%		

973 <sup>1</sup>Performance analysis included serum samples from n= 116 PCR positive subjects including 62  
 974 outpatients, 54 hospitalized subjects and 34 JMS hospitalized subjects

975 <sup>2</sup>Negative samples were drawn from the pre-2019 ARIC sera collection

976

977

978

979 **Table 4. SARS-2 spike/NP MMIA performance**

	SARS-CoV-2 PCR Status/Archival Sera			
		Positive	Negative	Total
SARS-CoV-2 NP IgG Antibody Test	Positive	139	5	144
	Negative	11	79	90
	Total	150	84	234
	Sensitivity	92.7%		
	Specificity	94.1%		

980

981

982

**Table 5. SARS-2/HCoV MMIA performance**

	SARS-CoV-2 PCR Status/Archival Sera			
		Positive	Negative	Total
SARS-CoV-2 spike IgG Antibody Test	Positive	68	0	68
	Negative	4	84	88
	Total	72	84	156
	Sensitivity	94.4%		
	Specificity	100%		

983

984

985

<sup>1</sup>IgG antibody test included serum samples collected 7-28 days post-onset from PCR positive EPICC and JMS participants.